Influenza Clinical Trial
Official title:
Collection & Extraction of Respiratory Specimens for the Validation of the Artus Influenza RG PCR Test
The study will be conducted with nasopharyngeal swab specimens collected prospectively from individuals suspected of having an acute respiratory tract infection caused by an Influenza virus. A series of standard viral culture tests validated for routine use in the clinical laboratory, as well as the CDC swine H1N1 test will be used to establish a collection of well characterized specimens. For each specimen four (4) aliquots will be prepared. One aliquot will be tested in real-time using the requisite viral culture reference methods, one aliquot will be used for H1N1 reference testing, one aliquot will be used to extract nucleic acid in real-time, and one aliquot of the UTM will be archived for the purpose of sequencing to confirm Influenza-positive specimens. The extracted nucleic acid and any remaining specimen will be stored at -70°C for later testing by the artus Influenza RG PCR test, or other investigational method(s).
Each year the morbidity and mortality associated with respiratory tract infections
fluctuates seasonally. This rise and fall is associated with the changing prevalence of
respiratory viruses in the population. Myriad respiratory viruses are responsible for these
infections. For example, Influenza Virus, Respiratory Syncytial Virus (RSV), Parainfluenza
Virus, Human Metapneumovirus, Rhinovirus, and Adenovirus have all been identified as causing
such infections. Numerous pathogenic subtypes have been identified within most of these
viral groups. Apart from supportive measure (e.g., bed rest, hydration, etc.), there are no
effective treatments for these viral infections; however, antiviral agents (e.g.,Tamiflu)
can be used to alleviate the severity of flu-like symptoms.
Each year the virus population fluctuates, and with it the antigenic presentation of the
dominant strains that circulate through the population. Epidemics arise when larger and
larger portions of the population do not have innate or acquired resistance to such
strain(s) in a given season. The World Health Organization (WHO) maintains a separate
website dedicated to tracking outbreaks of influenza, especially avian influenza
(https://www.who.int/fluvirus_tracker). Influenza outbreaks monitored in the hope that a
pandemic similar to the Spanish Flu of 1918 can be avoided; it is estimated that well over
25 million people died from the Spanish Flu. The United States government also maintains a
separate website with resources regarding the flu and pandemic related information
(http://www.pandemicflu.gov/). On June 11, 2009 the WHO raised the pandemic threat level to
6 in response to the global appearance of a new strain of swine Influenza A (subtype H1N1).
The rapidity with which the H1N1 virus has spread exemplifies the notion that quickly and
accurately identifying a viruses associated with an outbreak is critical to global public
health.
In the present study a collection of respiratory specimens that are well characterized will
be archived for later evaluation using the artus® Influenza RG PCR test. The artus Influenza
test is a real-time PCR test that identifies Influenza A, Influenza B, and Influenza Type
A/subtype H1N1 from nasopharyngeal swab specimens.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |